QIM
NBIX icon

Quantitative Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Quantitative Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,642
Closed -$650K – 430
2024
Q3 		$650K Buy
+5,642
New +$773K 0.06% 214
2023
Q1 		– Sell
-4,604
Closed -$549K – 295
2022
Q4 		$549K Buy
+4,604
New +$539K 0.1% 139
2021
Q4 		– Sell
-13,377
Closed -$1.28M – 386
2021
Q3 		$1.28M Buy
+13,377
New +$1.26M 0.12% 172
2020
Q1 		– Sell
-51,628
Closed -$5.55M – 727
2019
Q4 		$5.55M Buy
51,628
+11,055
+27% +$1.16M 0.17% 147
2019
Q3 		$3.66M Buy
+40,573
New +$3.79M 0.2% 149
2019
Q2 		– Sell
-2,700
Closed -$237K – 765
2019
Q1 		$237K Sell
2,700
-29,400
-92% -$2.46M 0.01% 589
2018
Q4 		$2.29M Buy
+32,100
New +$3.08M 0.12% 164
2018
Q3 		– Sell
-31,700
Closed -$3.11M – 795
2018
Q2 		$3.11M Buy
+31,700
New +$2.84M 0.06% 284
2018
Q1 		– Sell
-41,700
Closed -$3.23M – 867
2017
Q4 		$3.23M Sell
41,700
-25,800
-38% -$1.76M 0.05% 402
2017
Q3 		$4.14M Buy
+67,500
New +$3.56M 0.05% 370
2016
Q3 		– Sell
-16,600
Closed -$754K – 802
2016
Q2 		$754K Buy
16,600
+2,500
+18% +$115K 0.04% 480
2016
Q1 		$557K Buy
14,100
+8,600
+156% +$341K 0.03% 527
2015
Q4 		$311K Sell
5,500
-33,500
-86% -$1.7M 0.02% 581
2015
Q3 		$1.55M Buy
39,000
+31,100
+394% +$1.5M 0.12% 219
2015
Q2 		$377K Buy
+7,900
New +$335K 0.06% 288

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quantitative Investment Management's NBIX Position: Q4 2024 in Review

Quantitative Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 5,642 shares — an estimated $650K sold.

Quantitative Investment Management first reported a position in NBIX in Q2 2015 and held it in 15 quarters. The position peaked at $5.55M in Q4 2019. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Quantitative Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Quantitative Investment Management sold 5,642 Neurocrine Biosciences shares in Q4 2024, an estimated $650K.
  • Quantitative Investment Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 15 quarters.
  • Quantitative Investment Management's Neurocrine Biosciences position peaked at $5.55M in Q4 2019.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Quantitative Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.